BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12082456)

  • 21. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
    Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study.
    Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Selvaggi L; Katsaros D; Frigerio L; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Marforio G; Ballardini M; Lombardi AV; Sorio R; Tumolo S; Costa B; Magni G; Perrone F; Favalli G;
    Oncology; 2006; 71(5-6):320-6. PubMed ID: 17878745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
    Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
    J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Secondary debulking surgery and intraperitoneal chemotherapy in advanced or recurrent epithelial ovarian cancer].
    Plaisant N; Quenet F; Fabbro M; Gourgou S; Gutowski M; Saint-Aubert B; Rouanet P
    Gynecol Obstet Fertil; 2004 May; 32(5):391-7. PubMed ID: 15177208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study.
    Stiff PJ; Shpall EJ; Liu PY; Wilczynski SP; Callander NS; Scudder SA; Jazieh AR; Samlowski W; McCoy J; Alberts DS;
    Gynecol Oncol; 2004 Jul; 94(1):98-106. PubMed ID: 15262126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
    Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
    Gordon AN; Tonda M; Sun S; Rackoff W;
    Gynecol Oncol; 2004 Oct; 95(1):1-8. PubMed ID: 15385103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Multidisciplinary treatment of recurrent epithelial ovarian carcinoma and prognostic analysis].
    Huang X; Cai SM; Tang J; Li ZT; Zang RY
    Zhonghua Fu Chan Ke Za Zhi; 2004 Sep; 39(9):602-5. PubMed ID: 15498187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of refractory and recurrent ovarian cancer.
    Alberts DS
    Semin Oncol; 1999 Feb; 26(1 Suppl 1):8-14. PubMed ID: 10071969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma.
    Abaid LN; Goldstein BH; Micha JP; Rettenmaier MA; Brown JV; Markman M
    Oncology; 2010; 78(5-6):389-93. PubMed ID: 20798562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
    Sabbatini P; Sill MW; O'Malley D; Adler L; Secord AA;
    Gynecol Oncol; 2008 Dec; 111(3):455-60. PubMed ID: 18829087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term survival with whole abdominopelvic irradiation in platinum-refractory persistent or recurrent ovarian cancer.
    Cmelak AJ; Kapp DS
    Gynecol Oncol; 1997 Jun; 65(3):453-60. PubMed ID: 9190975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience.
    Leiser AL; Chi DS; Ishill NM; Tew WP
    Gynecol Oncol; 2007 Jun; 105(3):657-61. PubMed ID: 17395252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. One year maintenance of carboplatin in patients with epithelial ovarian cancer--a phase II study.
    Safra T; Kovner F; Barak N; Inbar MJ; Ron IG
    Isr Med Assoc J; 2006 Jan; 8(1):27-9. PubMed ID: 16450747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705.
    Bradley JD; Paulus R; Graham MV; Ettinger DS; Johnstone DW; Pilepich MV; Machtay M; Komaki R; Atkins J; Curran WJ;
    J Clin Oncol; 2005 May; 23(15):3480-7. PubMed ID: 15908657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
    J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
    Rocconi RP; Straughn JM; Leath CA; Kilgore LC; Huh WK; Barnes MN; Partridge EE; Alvarez RD
    Oncologist; 2006 Apr; 11(4):336-41. PubMed ID: 16614229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.
    Cadron I; Leunen K; Amant F; Van Gorp T; Neven P; Vergote I
    Gynecol Oncol; 2007 Aug; 106(2):354-61. PubMed ID: 17499348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer.
    Kim DW; Shyr Y; Shaktour B; Akerley W; Johnson DH; Choy H
    Lung Cancer; 2005 Nov; 50(2):235-45. PubMed ID: 16043262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.